Sonrotoclax for children with relapsed or refractory leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new oral drug, sonrotoclax, for children whose acute myeloid leukemia (AML) or B-cell acute lymphoblastic leukemia (ALL) has come back or not responded to at least two prior treatments. The drug targets a protein that helps cancer cells survive, potentially making them die off.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must have AML or B-cell ALL that has returned or not responded after at least two prior treatments.
- For ALL, one of those treatments must have included blinatumomab (a type of immunotherapy).
- Your child must have at least 5% leukemia cells in their bone marrow.
- Your child must be generally well enough, with adequate kidney, liver, and heart function.
- Your child cannot have leukemia that has spread to the brain or spinal fluid.
- Your child cannot have had a stem cell transplant within the last 90 days, or have active graft-versus-host disease (GVHD) requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone) for children and young adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back after treatment. It may help those whose leukemia has not responded to standard therapy or who have relapsed after a stem cell transplant or CAR-T therapy.
This trial tests an experimental drug called asciminib for children and young adults whose leukemia (a specific type of B-cell acute lymphoblastic leukemia with certain gene changes) has come back or not responded to treatment. The goal is to see if the drug is safe and effective for these patients.
This trial tests a new drug called Lonitoclax combined with azacitidine for people with AML that has come back or not responded to prior treatment. The study will see if the combination is safe and can help control the leukemia.
This Phase 2 study tests inotuzumab ozogamicin (InO), a cancer medicine, in children aged 1 to under 18 with a first relapse of ALL. It aims to find out how well and safely the medicine works when the leukemia comes back early.
This trial tests a combination of two targeted drugs (capivasertib and venetoclax) plus a steroid (dexamethasone) in children and young adults with blood cancers that have come back or not responded to treatment. The goal is to see if this drug combination is safe and works against the cancer.
This trial tests a new drug combination (ziftomenib, venetoclax, and azacitidine) in children and young adults with acute leukemia that has come back or not responded to treatment. It may help if your child's leukemia has certain genetic changes (like KMT2A, NPM1, or NUP98).
Hear when a new Relapsed Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.